Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study.

about

Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study.

Item

http://www.wikidata.org/entity/Q55035103

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Prognostic factors of afatinib ...... eal-world, large cohort study.

@en

Prognostic factors of afatinib ...... eal-world, large cohort study.

@nl

type

Item

label

Prognostic factors of afatinib ...... eal-world, large cohort study.

@en

Prognostic factors of afatinib ...... eal-world, large cohort study.

@nl

prefLabel

Prognostic factors of afatinib ...... eal-world, large cohort study.

@en

Prognostic factors of afatinib ...... eal-world, large cohort study.

@nl

P1476

Prognostic factors of afatinib ...... real-world, large cohort study

@en

P2093

Chao-Chi Ho

http://www.w3.org/2001/XMLSchema#string

Wei-Yu Liao

http://www.w3.org/2001/XMLSchema#string

P2860

Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.

P304

23749-23760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25255

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29805772

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5955108

http://www.w3.org/2001/XMLSchema#string